A successful Ph2 for myelofibrosis (SNT-5505) will see us taken out, most likely. This is the interim data being presented in December 2024 - 4 months away!
But if not a buyout, a licensing arrangement or partnership are most likely. A CR could be an option if we want to keep it all in-house and take the product to market ourselves, which is also a possibility, but a lot of money, time and effort to do so.
Add to My Watchlist
What is My Watchlist?
